Navigation Links
Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the voluntary recall of a single lot of OFIRMEV® (acetaminophen) injection. Cadence has notified the U.S. Food and Drug Administration of the recall.

The recall of OFIRMEV lot number V005710 was initiated due to the presence of an unidentified, visible particle in one vial of this lot during routine stability testing.  Lot V005710 was distributed by Cadence to hospitals, wholesalers and distributors beginning in January 2011, and Cadence believes that fewer than 1,000 vials currently remain in the marketplace. Cadence has not received any reports of adverse patient events associated with particulate matter in the product, and has undertaken the recall as a precautionary measure.  

"We regret that some of our customers experienced short-term supply delays due to our temporary suspension of shipments from the supplier of lot V005710," said Scott Byrd, Chief Commercial Officer of Cadence. "Fortunately, we were successful in our efforts to accelerate shipments of OFIRMEV from another supplier, which allowed us to quickly resume normal shipments of the product. We do not anticipate any further supply delays."

Customer Recall ContactCustomers with questions regarding this recall should call 1-866-338-4070.About OFIRMEV® (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. For more information about Cadence, please visit www.cadencepharm.com.

Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: estimates of the number of vials of lot V005710 that currently remain in the marketplace and expectations regarding the supply of OFIRMEV. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from the company's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is its only product; Cadence's ability to ensure an adequate and continued supply of OFIRMEV to meet anticipated market demand; the risk that if Cadence's contract manufacturers fail to meet its requirements for OFIRMEV, Cadence may be unable to meet market demand and may lose potential revenues; the potential that customers' perception of OFIRMEV or Cadence's relationships with its customers may be damaged by the recall; costs, re-stocking expenses and potential product liability claims that may be associated with the recall; the potential for additional recalls,  supply disruptions, or manufacturing changes for OFIRMEV; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc.

 Contact:

William R. LaRue

Kelli France 

SVP & Chief Financial Officer

Media Relations 

Cadence Pharmaceuticals, Inc.

WCG 

Phone: 858-436-1400

Phone: 415-946-1076


'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical
2. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
3. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
6. Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
7. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
9. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Jefferies 2011 Global Healthcare Conference on June 9, 2011
11. Cadence, Inc. Announces Major Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... PUNE, India , May 30, 2016 /PRNewswire/ ... research report "Healthcare Analytical Testing Services Market by ... Monitoring, Bioanalytical Services), by End User (Pharmaceutical Companies, ... published by MarketsandMarkets, The market witnessed healthy growth ... grow at a CAGR of 11.3% between 2016 ...
(Date:5/30/2016)... , May 30, 2016 Eye expert ... of premature babies to seek an eye examination ... condition     Moorfields Eye Hospital Dubai, ... London , has identified premature babies as a ... because of their particular vulnerability to retinopathy of prematurity (ROP). ROP ...
(Date:5/27/2016)... 2016 Kitov Pharmaceuticals ... on late-stage drug development, today announced the completion ... pivotal batches required for registration of KIT-302 with ... follows Kitov,s announcement in December 2015, ... its primary efficacy endpoint. "We are ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... May 30, 2016 , ... Another ER facility operated ... Plano, located at 3960 Legacy Drive, Plano, TX and is open 24 hours daily. ... Commerce followed by a medical open house. The Jasper High School band entertained attendees ...
(Date:5/29/2016)... (PRWEB) , ... May 29, 2016 , ... Whole Health ... Amazon.com, their new KlipPro KP-240L clipper is available to the public. This is an ... is substantially wider than the average clipper. , Everything about this product is concentrated ...
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... SuperCloset is ... all too well the day to day issues, struggles and obstacles veterans’ need to ... Helping Veterans Grow Project provides active or retired military veteran(s) with a donated SuperCloset ...
(Date:5/28/2016)... AL (PRWEB) , ... May 28, 2016 , ... May ... US Open Martial Arts Fighting Challenge with theme event of “K Warriors” on June ... Mobile, AL 36608. , The event is sponsored and hosted by Shaolin Institute ...
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... In a part of the city where’s ... city’s new farm-to-table Kelowna restaurants is hoping to attract diners with a taste ... & Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing ...
Breaking Medicine News(10 mins):